Prognostic Implication of Metabolic Syndrome in Patients with Nasopharyngeal Carcinoma: A Large Institution-Based Cohort Study from an Endemic Area

References

• Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64–80. doi:10.1016/S0140-6736(19)30956-031178151
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun Y, Ma J. Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma. Cancer Commun. 2019;39:39. doi:10.1186/s40880-019-0385-5
   Web of Science ®Google Scholar
• Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional tow-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80:661–668. doi:10.1016/j.ijrobp.2010.03.02420643517
   PubMed Web of Science ®Google Scholar
• Li R, Li W, Lun J, et al. Prevalence of metabolic syndrome in Mainland China: a meta-analysis of published studies. BMC Public Health. 2016;16:296. doi:10.1186/s12889-016-2870-y27039079
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35:2402–2411. doi:10.2337/dc12-033623093685
   PubMed Web of Science ®Google Scholar
• Li Y, Wang Y, Zhuang Y, et al. Serum metabolomic profiles associated with untreated metabolic syndrome patients in the Chinese population. Clin Transl Sci. 2020;13(6):1271–1278.32543029
   PubMed Web of Science ®Google Scholar
• de Haas EC, Oosting SF, Lefrandt JD, Wolffenbuttel BH, Sleijfer DT, Gietema JA. The metabolic syndrome in cancer survivors. Lancet Oncol. 2010;11(2):193–203.20152771
   PubMed Web of Science ®Google Scholar
• Li P, Wang T, Zeng C, et al. Association between metabolic syndrome and prognosis of breast cancer: a meta-analysis of follow-up studies. Diabetol Metab Syndr. 2020;12:10. doi:10.1186/s13098-019-0514-y32015762
   PubMed Web of Science ®Google Scholar
• Hu D, Peng F, Lin X, et al. Preoperative metabolic syndrome is predictive of significant gastric cancer mortality after gastrectomy: the Fujian prospective investigation of cancer (FIESTA) study. EbioMed. 2017;15:73–80. doi:10.1016/j.ebiom.2016.12.004
   PubMed Web of Science ®Google Scholar
• Peng F, Hu D, Lin X, et al. Preoperative metabolic syndrome and prognosis after radical resection for colorectal cancer: the Fujian prospective investigation of cancer (FIESTA) study. Int J Cancer. 2016;39:2705–2713. doi:10.1002/ijc.30404
   Web of Science ®Google Scholar
• Chen D, Ji F, Xu QM, et al. Interaction of smoking and metabolic syndrome in increasing the recurrence risk of colorectal cancer in a Chinese male cohort: a retrospective study. Sci Rep. 2018;8:972. doi:10.1038/s41598-018-19322-029343809
   PubMed Web of Science ®Google Scholar
• Liu B, Cheng B, Wang C, Chen P, Cheng Y. The prognostic significance of metabolic syndrome and weight loss in esophageal squamous cell carcinoma. Sci Rep. 2018;8:10101. doi:10.1038/s41598-018-28268-229973636
   PubMed Web of Science ®Google Scholar
• Conteduca V, Caffo O, Galli L, et al. Association among metabolic syndrome, inflammation, and survival in prostate cancer. Urol Oncol. 2018;36:240. doi:10.1016/j.urolonc.2018.01.007
   Web of Science ®Google Scholar
• Chen Y, Zhang L, Liu W, Wang K. Case-control study of metabolic syndrome and ovarian cancer in Chinese population. Nutr Metab (Lond). 2017;14:21. doi:10.1186/s12986-017-0176-428261315
   PubMed Web of Science ®Google Scholar
• Kriegmair MC, Mandel P, Porubsky S, et al. Metabolic syndrome negatively impacts the outcome of localized renal cell carcinoma. Horm Cancer. 2017;8:127–134. doi:10.1007/s12672-017-0289-228247362
   PubMed Web of Science ®Google Scholar
• Zucchetto A, Taborelli M, Bosetti C, et al. Metabolic disorders and the risk of nasopharyngeal carcinoma: a case-control study in Italy. Eur J Cancer Prev. 2018;27:180–183. doi:10.1097/CEJ.000000000000028627479542
   PubMed Web of Science ®Google Scholar
• Bernhardt S, Bayerlová M, Vetter M, et al. Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors. Breast Cancer Res. 2017;19(1):112. doi:10.1186/s13058-017-0905-729020998
   PubMed Web of Science ®Google Scholar
• Sivanand S, Vander Heiden MG. Emerging roles for branched-chain amino acid metabolism in cancer. Cancer Cell. 2020;37(2):147–156. doi:10.1016/j.ccell.2019.12.01132049045
   PubMed Web of Science ®Google Scholar
• Hu JY, Yi W, Xia YF, Gao J, Liu ZG, Tao YL. Impact of pretherapy body mass index on prognosis of nasopharyngeal carcinoma. Ai Zheng. 2009;28:1043–1048. doi:10.5732/cjc.009.1041519799811
   PubMedGoogle Scholar
• Huang PY, Wang CT, Cao KJ, et al. Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: findings from a randomised trial. Eur J Cancer. 2013;49:1923–1931. doi:10.1016/j.ejca.2013.01.02723434149
   PubMed Web of Science ®Google Scholar
• Li W, Shen LJ, Chen T, et al. Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study. Chin J Cancer. 2016;35:75. doi:10.1186/s40880-016-0139-627507261
   PubMedGoogle Scholar
• OuYang PY, Zhang LN, Tang J, et al. Evaluation of body mass index and survival of nasopharyngeal carcinoma by propensity-matched analysis: an observational case-control study. Medicine. 2016;95:e2380. doi:10.1097/MD.000000000000238026765414
   PubMed Web of Science ®Google Scholar
• Lin YH, Chang KP, Lin YS, Chang TS. Evaluation of effect of body mass index and weight loss on survival of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. Radiat Oncol. 2015;10:136. doi:10.1186/s13014-015-0443-326122711
   PubMed Web of Science ®Google Scholar
• Guo G, Fu MS, Wei SX, Chen RW. Impact of diabetes mellitus on the risk and survival of nasopharyngeal carcinoma: a meta-analysis. Onco Targets Ther. 2018;11:1193–1201.29535542
   PubMed Web of Science ®Google Scholar
• Peng XS, Xie GF, Qiu WZ. Type 2 diabetic mellitus is a risk factor for nasopharyngeal carcinoma: a 1:2 matched case-control study. PLoS One. 2016;11:e0165131.27760202
   PubMed Web of Science ®Google Scholar
• Wang CT, Chen MY, Guo X, et al. Association between pretreatment serum high-density lipoprotein cholesterol and treatment outcomes in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: findings from a randomised trial. J Cancer. 2019;10:3618–3623.31333778
   PubMed Web of Science ®Google Scholar
• Yao JJ, He XJ, Lawrence WR, et al. Prognostic value of circulating lipoprotein in patients with locoregionally advanced nasopharyngeal carcinoma. Cell Physiol Biochem. 2018;48:285–292. doi:10.1159/00049172830011397
   PubMedGoogle Scholar
• Chang H, Wei JW, Chen K, et al. Apolipoprotein A-I is a prognosticator of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. J Cancer. 2018;9:702–710. doi:10.7150/jca.2283629556328
   PubMed Web of Science ®Google Scholar
• Luo XL, Zhong GZ, Hu LY, et al. Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma. Oncotarget. 2015;6:44037–44048. doi:10.18632/oncotarget.582326503474
   PubMed Web of Science ®Google Scholar
• Jiang R, Yang ZH, Luo DH, et al. Elevated apolipoprotein A-I levels are associated with favorable prognosis in metastatic nasopharyngeal carcinoma. Med Oncol. 2014;31:80. doi:10.1007/s12032-014-0080-y25023050
   PubMed Web of Science ®Google Scholar
• Tang Q, Hu QY, Piao YF, Hua YH. Correlation between pretreatment serum LDL-cholesterol levels and prognosis in nasopharyngeal carcinoma patients. Onco Targets Ther. 2016;9:2585–2591. doi:10.2147/OTT.S9807927217776
   PubMed Web of Science ®Google Scholar
• Yang P, Elhalawani H, Shi Y, et al. A large-scale retrospective study of the overall survival outcome in nasopharyngeal carcinoma with hypertension in Chinese population. Oncotarget. 2017;8:75577–75586. doi:10.18632/oncotarget.1748329088892
   PubMedGoogle Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674–1685.20587728
   PubMed Web of Science ®Google Scholar
• M’hamdi H, Baizig NM, ELHadj OE, et al. Usefulness of IGF-1 serum levels as diagnostic marker of nasopharyngeal carcinoma. Immunobiology. 2016;221:1304–1308. doi:10.1016/j.imbio.2016.05.00827312888
   PubMed Web of Science ®Google Scholar
• Wang R, Li H, Guo X, Wang Z, Liang S, Dang C. IGF-I induces epithelial-to-mesenchymal transition via the IGF-IR-Src-MicroRNA-30a-E-Cadherin pathway in nasopharyngeal carcinoma cells. Oncol Res. 2016;24:225–231. doi:10.3727/096504016X1464870144793127656832
   PubMed Web of Science ®Google Scholar
• Tworkoski K, Raab-Traub N. LMP1 promotes expression of insulin-like growth factor 1 (IGF1) to selectively activate IGF1 receptor and drive cell proliferation. J Virol. 2015;89:2590–2602. doi:10.1128/JVI.02921-1425520502
   PubMed Web of Science ®Google Scholar
• Wang T, Dong XM, Zhang FL, Zhang JR. miR-206 enhances nasopharyngeal carcinoma radiosensitivity by targeting IGF1. Kaohsiung J Med Sci. 2017;33:427–432. doi:10.1016/j.kjms.2017.05.01528865599
   PubMed Web of Science ®Google Scholar
• He X, Yan B, Liu S, et al. Chromatin remodeling factor LSH drives cancer progression by suppressing the activity of fumarate hydratase. Cancer Res. 2016;76:5743–5755. doi:10.1158/0008-5472.CAN-16-026827302170
   PubMed Web of Science ®Google Scholar
• Zhang J, Jia L, Liu T, et al. mTORC2-mediated PDHE1α nuclear translocation links EBV-LMP1 reprogrammed glucose metabolism to cancer metastasis in nasopharyngeal carcinoma. Oncogene. 2019;38:4669–4684. doi:10.1038/s41388-019-0749-y30745576
   PubMed Web of Science ®Google Scholar
• Lo AK, Dawson CW, Young LS, Ko CW, Hau PM, Lo KW. Activation of the FGFR1 signalling pathway by the Epstein-Barr virus-encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells. J Pathol. 2015;237:238–248. doi:10.1002/path.457526096068
   PubMed Web of Science ®Google Scholar
• Tan Z, Xiao L, Tang M, et al. Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy. Theranostics. 2018;8:2329–2347. doi:10.7150/thno.2145129721083
   PubMed Web of Science ®Google Scholar
• Lin TC, Chen YR, Kensicki E, et al. Autophagy: resetting glutamine-dependent metabolism and oxygen consumption. Autophagy. 2012;8(10):1477–1493. doi:10.4161/auto.2122822906967
   PubMed Web of Science ®Google Scholar
• Wegiel B, Vuerich M, Daneshmandi S, Seth P. Metabolic switch in the tumor microenvironment determines immune responses to anti-cancer therapy. Front Oncol. 2018;13(8):284. doi:10.3389/fonc.2018.00284
   Web of Science ®Google Scholar
• Guo Y, Lv B, Liu R, et al. Role of LncRNAs in regulating cancer amino acid metabolism. Cancer Cell Int. 2021;21(1):209. doi:10.1186/s12935-021-01926-833849550
   PubMed Web of Science ®Google Scholar
• Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27:2184–2195. doi:10.1093/annonc/mdw41027681864
   PubMed Web of Science ®Google Scholar
• Zhong S, Zhang X, Chen L, Ma T, Tang J, Zhao J. Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Cancer Treat Rev. 2015;41:554–567. doi:10.1016/j.ctrv.2015.04.00525890842
   PubMed Web of Science ®Google Scholar